An open-label, two-part Phase 2 clinical trial designed to evaluate galeterone in men whose mCRPC rapidly progressed following treatment with either abiraterone or enzalutamide

Trial Profile

An open-label, two-part Phase 2 clinical trial designed to evaluate galeterone in men whose mCRPC rapidly progressed following treatment with either abiraterone or enzalutamide

Planning
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Galeterone (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2016 According to Tokai Pharmaceuticals media release, the company intends to evaluate this planned study following the recommendation made by the independent Data Monitoring Committee (DMC) to discontinue ARMOR3-SV study (Profile 700252262).
    • 30 Mar 2016 According to Tokai Pharmaceuticals media release, company is planning to initiate this trial in the middle of 2016.
    • 30 Mar 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jun 2016, as per Tokai Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top